A Prospective Phase Ib/II Trial of Radiotherapy Combined With Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor in High-Risk Localized Soft Tissue Sarcoma (IRIS)
Latest Information Update: 23 Aug 2023
Price :
$35 *
At a glance
- Drugs Sintilimab (Primary) ; Surufatinib (Primary)
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- Acronyms IRIS
- 08 May 2023 New trial record